If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJardine Math.sr Regulatory News (JAR)

Share Price Information for Jardine Math.sr (JAR)

Share Price is delayed by 15 minutes
Get Live Data
62.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: $18.40b
JAR Live PriceLast checked at - London Stock Exchange

Intraday Jardine Math.sr Share Chart

Directorate Change

5 Mar 2020 09:21

RNS Number : 1288F
Jardine Matheson Hldgs Ltd
05 March 2020
 

Jardine Matheson Holdings Limited

Directorate Change

 

Jardine Matheson Holdings Limited (the 'Company') announces that, with effect from 15th June 2020, the roles of Executive Chairman and Managing Director, which have been held on a combined basis by Ben Keswick since December 2018, will revert to being separate roles.

 

Ben Keswick will remain as Executive Chairman and John Witt, currently Group Finance Director, will take on the role of Managing Director.

 

John joined Jardines in 1993 and held a range of senior roles across the Group's core businesses and geographies, including as chief financial officer of Hongkong Land and Mandarin Oriental, before being appointed to the Jardine Matheson Board in 2016.

 

John will also be a director of Jardine Strategic Holdings Limited and the Group's listed subsidiaries, Hongkong Land Holdings Limited, Dairy Farm International Holdings Limited and Mandarin Oriental International Limited. He will also continue to be a commissioner of Astra and chairman of the Astra Excom.

 

Graham Baker will replace John as Group Finance Director and will join the Group on 1st June 2020 from Smith + Nephew in the United Kingdom, where he has been a board member and chief financial officer since March 2017. Graham will join the Board of the Company.

 

Prior to joining Smith + Nephew, Graham worked for 20 years for AstraZeneca PLC in a range of senior roles in the UK and internationally, including in Japan and Singapore, and then as chief financial officer of generic pharmaceuticals company Alvogen.

 

Commenting on the changes, Ben Keswick said:

"I am confident that these appointments will strengthen and enhance the effectiveness of the Group's leadership as we respond to the challenges and opportunities we face in positioning Jardines for continuing long term success."

 

- end -

 

For further information please contact

 

Investor enquries:

Jonathan Lloyd

Jardine Matheson Limited

 

(852) 2843 8223

 

Media enquiries:

Brunswick

Tom Burns

 

(44) 207 404 5959

David Ashton

(852) 3512 5063

 

This and other Group announcements can be accessed at www.jardines.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAUPUBAWUPUURA
Date   Source Headline
28th Jan 202611:31 amRNSHolding(s) in Company
27th Jan 202610:29 amRNSTransaction in Own Shares
27th Jan 202610:25 amRNSDirector/PDMR Shareholding
26th Jan 202611:22 amRNSTransaction in Own Shares
23rd Jan 202610:21 amRNSTransaction in Own Shares
22nd Jan 20269:59 amRNSTransaction in Own Shares
21st Jan 202610:47 amRNSTransaction in Own Shares
21st Jan 20269:48 amRNSDirector/PDMR Shareholding
21st Jan 20269:39 amRNSGBP Exchange Rate for Scheme Value
20th Jan 202612:41 pmRNSCancellation of the Listings of Mandarin Oriental
20th Jan 20269:45 amRNSTransaction in Own Shares
20th Jan 20269:36 amRNSHolding(s) in Company
19th Jan 20261:45 pmRNSCompletion of Acquisition by Jardine Strategic
19th Jan 202610:24 amRNSTransaction in Own Shares
16th Jan 202611:05 amRNSDirector/PDMR Shareholding
16th Jan 202610:24 amRNSTransaction in Own Shares
16th Jan 20267:00 amRNSCourt Sanction of Scheme of Arrangement
15th Jan 202610:11 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20269:49 amRNSDirector/PDMR Shareholding
31st Dec 20257:23 amRNSTotal Voting Rights
31st Dec 20257:23 amRNSTotal Voting Rights
31st Dec 20257:22 amRNSUpdate on OCB Sale and Acquisition Timeline
31st Dec 20257:22 amRNSUpdate on OCB Sale and Acquisition Timeline
29th Dec 202511:11 amRNSTransaction in Own Shares
29th Dec 202511:11 amRNSTransaction in Own Shares
23rd Dec 202510:02 amRNSDirector/PDMR Shareholding
23rd Dec 202510:02 amRNSDirector/PDMR Shareholding
18th Dec 202510:24 amRNSDirector/PDMR Shareholding
11th Dec 202510:40 amRNSDirector/PDMR Shareholding
10th Dec 20259:21 amRNSDirector/PDMR Shareholding
8th Dec 20253:47 pmRNSResults of Court Meeting & Special General Meeting
28th Nov 20259:37 amRNSTotal Voting Rights
21st Nov 202510:11 amRNSInterim Management Statement
21st Nov 20259:58 amRNSInterim Management Statement
20th Nov 20259:30 amRNSINTERIM MANAGEMENT STATEMENT
14th Nov 202511:37 amRNSReplacement: Publication of Shareholder Circular
14th Nov 20259:38 amRNSAnnouncement (Publication of Shareholder Circular)
14th Nov 20259:21 amRNSDirector/PDMR Shareholding
10th Nov 202510:31 amRNSJC&C Interim Management Statement
6th Nov 202510:48 amRNSTransaction in Own Shares
4th Nov 20251:14 pmRNSTransaction in Own Shares
3rd Nov 20257:00 amRNSProposed Share Buyback
31st Oct 202510:26 amRNSPT Astra 2025 Third Quarter Financial Statements
31st Oct 20259:48 amRNSPT DFI RETAIL NUSANTARA TBK 2025 9-MONTHS RESULTS
31st Oct 20259:26 amRNSDirector/PDMR Shareholding
31st Oct 20259:23 amRNSTotal Voting Rights
30th Oct 20259:20 amRNSINTERIM MANAGEMENT STATEMENT
22nd Oct 202511:11 amRNSDirector/PDMR Shareholding
17th Oct 202511:18 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.